Monte Rosa Therapeutics (GLUE) Competitors $5.05 -0.03 (-0.59%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$5.05 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. MLYS, RCUS, PAHC, ARDX, WVE, COLL, SYRE, SNDX, GYRE, and AVDLShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Phibro Animal Health (PAHC), Ardelyx (ARDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), Syndax Pharmaceuticals (SNDX), Gyre Therapeutics (GYRE), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Its Competitors Mineralys Therapeutics Arcus Biosciences Phibro Animal Health Ardelyx Wave Life Sciences Collegium Pharmaceutical Spyre Therapeutics Syndax Pharmaceuticals Gyre Therapeutics Avadel Pharmaceuticals Monte Rosa Therapeutics (NASDAQ:GLUE) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends. Does the MarketBeat Community prefer GLUE or MLYS? Mineralys Therapeutics received 4 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 86.96% of users gave Mineralys Therapeutics an outperform vote while only 47.06% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1647.06% Underperform Votes1852.94% Mineralys TherapeuticsOutperform Votes2086.96% Underperform Votes313.04% Do analysts prefer GLUE or MLYS? Monte Rosa Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 206.93%. Mineralys Therapeutics has a consensus price target of $32.25, suggesting a potential upside of 107.40%. Given Monte Rosa Therapeutics' higher possible upside, research analysts clearly believe Monte Rosa Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk & volatility, GLUE or MLYS? Monte Rosa Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Do insiders & institutionals have more ownership in GLUE or MLYS? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 6.9% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is GLUE or MLYS more profitable? Monte Rosa Therapeutics' return on equity of -62.68% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% Mineralys Therapeutics N/A -67.97%-62.40% Which has higher valuation & earnings, GLUE or MLYS? Monte Rosa Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$159.49M1.95-$135.35M$0.0863.13Mineralys TherapeuticsN/AN/A-$177.81M-$3.73-4.17 Does the media prefer GLUE or MLYS? In the previous week, Mineralys Therapeutics had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 2 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.96 beat Mineralys Therapeutics' score of 0.91 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMonte Rosa Therapeutics beats Mineralys Therapeutics on 9 of the 14 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$310.63M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-2.7633.3227.1220.06Price / Sales1.95469.84412.30157.10Price / CashN/A168.6838.2534.64Price / Book1.413.457.064.70Net Income-$135.35M-$72.35M$3.23B$247.88M7 Day Performance9.31%6.23%2.86%2.63%1 Month Performance18.27%16.53%9.07%6.36%1 Year Performance21.39%-16.90%31.45%14.05% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.3885 of 5 stars$5.05-0.6%$15.50+206.9%+18.0%$310.63M$159.49M-2.7690MLYSMineralys Therapeutics3.3374 of 5 stars$15.87+0.2%$38.00+139.5%+19.7%$1.03BN/A-4.3628Positive NewsAnalyst ForecastRCUSArcus Biosciences2.5159 of 5 stars$9.57+4.8%$25.67+168.2%-41.9%$1.01B$141M-3.03500Options VolumeAnalyst RevisionGap UpPAHCPhibro Animal Health3.8832 of 5 stars$24.63+0.5%$20.00-18.8%+45.6%$997.14M$1.19B51.251,860Positive NewsARDXArdelyx3.9734 of 5 stars$4.02+2.7%$10.39+158.8%-44.2%$960.37M$361.71M-25.0990Insider TradeAnalyst RevisionWVEWave Life Sciences4.4506 of 5 stars$6.19+2.3%$21.17+241.9%+16.0%$954.86M$104.94M-5.58240Positive NewsAnalyst ForecastAnalyst RevisionCOLLCollegium Pharmaceutical4.0333 of 5 stars$29.25+1.2%$43.80+49.8%-8.8%$940.50M$664.28M12.62210Positive NewsInsider TradeSYRESpyre Therapeutics2.1734 of 5 stars$15.58+3.3%$53.40+242.7%-52.6%$939.10M$890K-2.0973SNDXSyndax Pharmaceuticals3.0091 of 5 stars$10.65+5.2%$35.91+237.2%-43.6%$916.32M$43.72M-2.93110Positive NewsGYREGyre Therapeutics0.367 of 5 stars$9.59+1.6%N/A-21.8%$901.76M$100.64M480.9040Short Interest ↓AVDLAvadel Pharmaceuticals2.171 of 5 stars$9.24+2.1%$19.43+110.2%-35.2%$892.32M$194.45M-11.6870Positive NewsAnalyst Revision Related Companies and Tools Related Companies MLYS Alternatives RCUS Alternatives PAHC Alternatives ARDX Alternatives WVE Alternatives COLL Alternatives SYRE Alternatives SNDX Alternatives GYRE Alternatives AVDL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
